Vascular Targeting Viral Therapy Augments Pd-L1 Checkpoint Blockade Anti-Tumor Activity

被引：0
|
作者：
Breitbart, Eyal [1 ]
Mendel, Itzhak [1 ]
Yacov, Niva [1 ]
机构：
[1] VBL Therapeut, Or Yehuda, Israel
来源：
MOLECULAR THERAPY | 2017年 / 25卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
585
引用
收藏
页码：270 / 271
页数：2
相关论文
共 50 条
  • [1] Dual targeting autoinflammation and PD-L1/L2 immune checkpoint by EGCG augments anti-tumor effects in melanoma
    Li, Y.
    Menon, D. Ravindran
    Mathew, D.
    Torres, R.
    Fujita, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S145 - S145
  • [2] Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade
    Jiang, Yuying
    Yang, Yongbing
    Hu, Yingchao
    Yang, Rui
    Huang, Jiajia
    Liu, Yi
    Wu, Yuqing
    Li, Sheng
    Ma, Chunmei
    Humphries, Fiachra
    Wang, Bingwei
    Wang, Xi
    Hu, Zhibin
    Yang, Shuo
    CELL REPORTS, 2022, 41 (04):
  • [3] MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
    Ebert, Peter J. R.
    Cheung, Jeanne
    Yang, Yagai
    McNamara, Erin
    Hong, Rebecca
    Moskalenko, Marina
    Gould, Stephen E.
    Maecker, Heather
    Irving, Bryan A.
    Kim, Jeong M.
    Belvin, Marcia
    Mellman, Ira
    IMMUNITY, 2016, 44 (03) : 609 - 621
  • [4] PD-L1 blockade enhances anti-tumor efficacy of NK cells
    Oyer, Jeremiah L.
    Gitto, Sarah B.
    Altomare, Deborah A.
    Copik, Alicja J.
    ONCOIMMUNOLOGY, 2018, 7 (11):
  • [5] A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity
    Luan, Yan
    Chai, Dafei
    Peng, Jianjian
    Ma, Shuli
    Wang, Min
    Ma, Hui
    Li, Xiang
    Fu, Shilong
    Pan, Xiaolong
    Wang, Xiaoxiao
    Qin, Songbing
    Xu, Ting
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2016, 31 : 248 - 256
  • [6] FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
    Dahan, Rony
    Sega, Emanuela
    Engelhardt, John
    Selby, Mark
    Korman, Alan J.
    Ravetch, Jeffrey V.
    CANCER CELL, 2015, 28 (03) : 285 - 295
  • [7] PD-L1 Checkpoint Blockade Using a Single-Chain Variable Fragment Targeting PD-L1 Delivered by Retroviral Replicating Vector Enhances Anti-Tumor Effect in Cancer Models
    Lin, Amy H.
    Yagiz, Kader
    Hofacre, Andrew
    Munday, Anthony W.
    Espinoza, Fernando Lopez
    Mendoza, Daniel
    Burrascano, Cynthia
    Gruber, Harry E.
    Mitchell, Leah A.
    Jolly, Douglas J.
    MOLECULAR THERAPY, 2018, 26 (05) : 54 - 54
  • [8] Enhancement of the anti-tumor activity of CEA TCB via combination with checkpoint blockade by PD-L1 and interleukin-2 variant immunocytokine
    Bacac, Marina
    Colombetti, Sara
    Fahrni, Linda
    Fauti, Tanja
    Nicolini, Valeria
    Sam, Johannes
    Papastogiannidis, Petros
    Le Clech, Marine
    Miot, Xavier
    Waldhauer, Inja
    Rommel, Karolin
    Gerdes, Christian
    Klein, Christian
    Umana, Pablo
    CANCER RESEARCH, 2017, 77
  • [9] Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy
    Zhang, Weinan
    He, Zhiqiang
    Liang, Fucheng
    Gong, Jie
    Tan, Liuchang
    Yang, Juan
    Song, Siji
    Xie, Luoyingzi
    Lu, Yuangang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (18) : 16763 - 16778
  • [10] Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy
    Weinan Zhang
    Zhiqiang He
    Fucheng Liang
    Jie Gong
    Liuchang Tan
    Juan Yang
    Siji Song
    Luoyingzi Xie
    Yuangang Lu
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 16763 - 16778
12345